Literature DB >> 9219927

Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors.

S E Barrie1, B P Haynes, G A Potter, F C Chan, P M Goddard, M Dowsett, M Jarman.   

Abstract

Two potent non-steroidal inhibitors (CB7645 and CB7661) of human cytochrome P450(17alpha) were tested for in vivo activity in WHT mice. There were no signs of toxicity, but there was no effect on the androgen-dependent organs. The pharmacokinetics and biochemistry of the compounds in mice were investigated. Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h. CB7645 produced some decrease in plasma testosterone at 4 h, but this was not sustained. When tested in vitro against the WHT testicular enzyme, the CB7645 and CB7661 were competitive inhibitors with K(i) values of 10 and 13 nM, respectively. However, the K(m) for the substrate progesterone was lower at 4.3 nM. These data indicate that, for effective and continuous inhibition of the murine cytochrome P450(17alpha) enzyme, higher peak levels of the compounds would be required, and these levels would need to be maintained throughout the treatment period.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219927     DOI: 10.1016/s0960-0760(96)00225-7

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  12 in total

Review 1.  New agents in the arsenal to fight castrate-resistant prostate cancer.

Authors:  Erin E Ezzell; Kuang S Chang; Benjamin J George
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

2.  [Castration-resistant prostate cancer (CRPC)].

Authors:  W Loidl; F Luger; A Roosen
Journal:  Urologe A       Date:  2014-03       Impact factor: 0.639

3.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

Review 4.  [Testosterone in the management of metastatic prostate cancer].

Authors:  J M Wolff; H P Schmid
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

5.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

6.  Functional link between bone morphogenetic proteins and insulin-like peptide 3 signaling in modulating ovarian androgen production.

Authors:  Claire Glister; Leanne Satchell; Ross A D Bathgate; John D Wade; Yanzhenzi Dai; Richard Ivell; Ravinder Anand-Ivell; Raymond J Rodgers; Philip G Knight
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

Review 7.  Current treatment strategies for advanced prostate cancer.

Authors:  Kazumasa Komura; Christopher J Sweeney; Teruo Inamoto; Naokazu Ibuki; Haruhito Azuma; Philip W Kantoff
Journal:  Int J Urol       Date:  2017-12-20       Impact factor: 3.369

8.  A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer.

Authors:  Ravinder Clayton; Jackson Wu; Daniel Y Heng; Scott A North; Urban Emmenegger; Sebastien Hotte; Kim Chi; Rob Zielinski; Humaid Al-Shamsi; Leo Chen; Bernhard Eigl
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

9.  Castration-resistant prostate cancer: mechanisms, targets, and treatment.

Authors:  Teresa Maria Santos Amaral; Daniela Macedo; Isabel Fernandes; Luis Costa
Journal:  Prostate Cancer       Date:  2012-03-05

Review 10.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.

Authors:  R Ferraldeschi; J Welti; J Luo; G Attard; J S de Bono
Journal:  Oncogene       Date:  2014-05-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.